Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway
J. Clin. Invest. Jennifer L. Gommerman, et al. 110:1359 doi:10.1172/JCI15975 [Go to this article.]

Figure 5
LTβR-Ig treatment results in changes in the splenic MZ. Spleens from untreated (a, c, e, g) and treated (8 mg/kg LTβR-Ig) animals (b, d, f, h) were stained with Asm-1 (red) and anti-IgD (green) (a, b), or stained with Asm-1 (red) and anti-VCAM-1 (green) (c–f), or stained with anti-IgD (green) with anti–VCAM-1 (green) (g–h). The i-MZ is identified (a) with arrows. The Asm-1/VCAM-1–positive MZ is identified (c, e, g) with arrows. Representative spleens were examined by fluorescence microscopy and were photographed at ×100 (a, b, c, d, g, h) or 200× (e–f).